(b) what are the reasons that the concerned producers were not issued show cause notice for marketing these products without price approval;

(c) what were their prices under DPCO, 1979 and what are their present prices; and

(d) what is their sales turnover based on the latest available ORG?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) The required details to the extent available would be collected and laid on the Table of the House.

(d) Sales turnover is not monitored.

Sales turn over of Formulations

3004. SHRI RAOOF VALIULLAH: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3280 given in the Rajya Sabha on the 22nd August, 1988 and state:

(a) whether it is a fact that Serial numbers 12 and 13 of Form-2 Serial Number 4(f) of Form-4 and Serial Number 5 of Form-6 contain details of number of packs sold and sales turn over of both scheduled and non-scheduled formulations;

(b) whether it is also a fact that his Ministry is obtaining these forms;

(c) if so, what are the reasons for not providing the details asked for sales turnover when the same are available;

(d) what are the details of sales turn over of Dilosyn, Banadryl, Evion, Berin, Celin, Glynase, Durabolin, Decadurabolin, Ildaman, Duadilan and Neosporin;

(e) how many of these products are exempted from price control and what are the basis of exemption;

(f) whether it is a fact that his Ministry received number of representations for inclusion of these products due to non-fulfilment of exclusion criteria; and

(g) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (d) Under the provisions of DPCO, 1987, manufacturers are required to submit such information. However, sales turnover is not monitored.

(e) All the referred formulations are price decontrolled as per the provisions of DPCO, 1987.

(f) and (g) All representations received in this regard were forwarded to Kelkar Committee and the Supplementary report submitted by the committee is under examination.

Production and import of Dexamethasone

3005. DR. G. VIJAYA MOHAN REDDY: Will the Minister of INDUSTRY be pleased to state:

(a) the stage from which Dexamethasone and its salts are being manufactured in the country;

(b) since when these are being produced;

(c) what is the import content in the production of each Kg. of Dexamethasone;

(d) what was the price fixed for Dexamethasone and ite salts under DPCO, 1979 and what is the present price;

(e) what was the price at which the same were sold by the producers under DPCO, 1979;

(f) whether it is a fact that Dexamethasone and its salts are allowed for import;

(g) if so, the quantity imported during the last three years, year-wise along with CIF price per gram per year;

(h) whether his Ministry fixed prices of formulations based on these drugs;

(i) if so, when the price was fixed for each formulation; and

(j) what is the price at which each is being sold at present?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) Dexamethasone is being produced from intermediate stage since several years.

(c) Such details are not monitored by this Ministry.

(d) The prices fixed under DPCO, 1979 for Dexamethasone pure and Dexamethasone 21-phosphate are Rs. 51 30 and Rs. 55.10 per gram respectively. No prices have been fixed under DPCO, 1987.

(e) The prices maintained by M/s. Merand Ltd. under DPCO, 1979 (previously M/s. Merck Sharp and Dohme of India Ltd.) as per the stay granted by the Delhi High Court are Rs. 92.62 and Rs. 195.37 per gram for Dexamethasone pure and Dexamethasone 21-phosphate respectively.

(f) Names of drugs allowed for import are given in the Export-Import Policy, April 1988 to March, 1991 which was laid on the Table of the House.

(g) Details of imports of drugs such as quantity and CIF prices are published in the "Monthly Statistics for Foreign Trade in India", Vol. II, copies of which are available in the parliament Library.

(h) to (j) The prices of formulations based on Dexamethasone could not be fixed under DPCO, 1979 due to stay granted by the Delhi High Court.

DPE Amount due against M/s. Pfizer

3006. SHRI RAOOF VALIULLAH: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3286 given in the Rajya Sabha on the 22nd August, 1988 and state;

(a) whether it is a fact that the amount due against M/s. Pfizer in DPEA has been calculated by the team after compiling details of products involved, their fixed prices, charged prices, production and recovery rate;

(b) what are the details of reduction of liability of this company; and

(c) what was the original liability?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The special team finalised the amount recoverable from M/s. Pfizer Ltd., after verifying the records of the company.

(b) The special team took into account the under charged prices by the company during the period April to November, 1981.

(c) The tentative amount assessed by the team was Rs. 99,07,731,00.

Determination of Amounts due under DPEA

3007. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question No. 3292 given in the Rajya Sabha on the 22nd August, 1988 and state:

(a) whether it is a fact that in respect of amounts due under the Drug Price Equalisation Account under para 7(2) neither any determination of amount nor any recovery has been carried out for the last two years;

(b) if so, what are the details of determination of amount and recovery made;

(c) what are the names of identified drugs, amount due in respect of each under para 7(2) of DPCO, 1979 and when was the last communication issued to the concerned company;

(d) whether it is a fact that his Ministry worked out amount due under para 7(2) from IDPL and HAL; and

(e) if so, what are the names of the drugs/formulations involved and the amount recovered from each upto 31st October, 1988?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) The tentative amounts recoverable from companies under Para 7(2) of DPCO, 1979 to the extent information is available, are given in the enclosed Statement. (*See* below) No amount has so far been recovered (except M/s. Fulford India Ltd.